Vascular malformations: Repurposing the role of anti-cancer targeted molecular inhibitors

BJMO - volume 16, issue 6, october 2022

E. Seront MD, PhD, V. Dekeuleneer MD, A. van Damme MD, PhD, L. Boon MD, PhD, M. Vikkula MD, PhD


Vascular malformations are rare diseases that result from anomalies in the angiogenesis process. They are subdivided into capillary, lymphatic, venous, arteriovenous, and mixed malformations, according to the type of affected vessels. Until a few years ago, therapeutic options were limited to sclerotherapy and/or surgery, but these treatments are rarely curative or not feasible. Most vascular malformations are caused by inherited or somatic mutations in various genes. These mutations are similar to oncogenic mutations detected in cancer, leading to hyperactivity of important signalling pathways, including MAPK and PI3K/AKT/mTOR cascades. This article highlights the role of targeted molecular inhibitors as therapies for vascular anomalies via repurposing of anticancer drugs.

(BELG J MED ONCOL 2022;16(6):293–99)

Read more

The strategic plan for paediatric cancer treatment and clinical research development in Belgium

BJMO - volume 13, issue 1, february 2019

A. van Damme MD, PhD, B. De Moerloose MD, PhD, B. Brichard MD, PhD, A. Ferster MD, D. Heenen , G. Laureys MD, PhD, K. Norga , C. Piette MD, PhD, J. van der Werff ten Bosch , A. Uyttebroeck MD, PhD

Childhood cancer can be cured in a good proportion of patients, but outcome rates are still unsatisfactory for specific cancer types and for resistant or relapsed disease. Collaborative clinical research is required for further outcome improvement as well as easier access for children to innovative treatments. Moreover, clinical care standards and clinical research infrastructure in Belgium should be optimised and structurally financed to reach the level proposed by international professional and scientific organisations. In this strategic plan, obstacles are analysed, and solutions for improved childhood cancer care and clinical research in Belgium are proposed.

(BELG J MED ONCOL 2019;13(1):21–26)

Read more